BioAdaptives, Inc. (OTC: BDPT) announced the upcoming commercial launch of XcellaraHeart™, a cardiovascular wellness supplement that combines the company’s Xcellara™ stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The product is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August.
The Xcellara™ base is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, with zero adverse effects on more than twenty blood parameters. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair biology. The combination is designed around a two-part cardiovascular wellness strategy: stem/progenitor cell mobilization coupled with cardiovascular signaling support.
BioAdaptives noted that a scientific evidence dossier detailing the formulation is available on the company’s product website at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara™ base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two.
The announcement is significant because it represents the commercialization of a dietary supplement that has undergone rigorous clinical testing, which is rare in the nutraceutical industry. The 268.8% increase in circulating stem and progenitor cells observed in the clinical trial suggests that the product could play a role in supporting the body’s natural regenerative processes, particularly for cardiovascular health. Cardiovascular disease remains the leading cause of death globally, and many consumers seek non-pharmaceutical approaches to support heart health. If the combination with Tanshinone IIA proves effective in enhancing cellular repair mechanisms, XcellaraHeart could offer a novel option for individuals looking to maintain cardiovascular wellness.
For the dietary supplement industry, this launch underscores a trend toward evidence-based formulations. BioAdaptives’ investment in a randomized, double-blind, placebo-controlled trial sets a high bar for competitors and may influence regulatory expectations or consumer demand for scientifically validated products. The company’s Xcellara product line includes seven targeted formulas for cardiac, joint, neural, dermal, longevity, and stress-resilience applications, suggesting a broader strategy to address multiple health concerns through stem cell mobilization.
The full press release is available at https://nnw.fm/G14S7. For more information about BioAdaptives, visit www.bioadaptives.com.
